Treatment of recurrent epistaxis in HHT

Current Pharmaceutical Design

Volumn 12, Issue 10, 2006, Pages 1237-1242

  Giesthoff, Urban W ^a   Fiorella, M L ^b   Fiorella, R ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Hereditary haemorrhagic telangiectasia; Laser therapy; Rendu Osler Weber disease; Review; Septodermoplasty

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; DANAZOL; DEXPANTHENOL; ESTROGEN; ETHIBLOC; ETHINYLESTRADIOL; FIBRIN GLUE; HEPARIN; HORMONE; PROGESTERONE; RESPIRATORY TRACT AGENT; SCLEROSING AGENT; TRANEXAMIC ACID; XYLOMETAZOLINE;

ARGON PLASMA COAGULATION; ARTERY LIGATION; ARTIFICIAL EMBOLISM; BIOLOGICAL MODEL; BLOOD FLOW; BRACHYTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE MODEL; DRUG HYPERSENSITIVITY; EPISTAXIS; HUMAN; LASER COAGULATION; NONHUMAN; OINTMENT; PATHOPHYSIOLOGY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RECURRENT DISEASE; RENDU OSLER WEBER DISEASE; REVIEW; SURGICAL TECHNIQUE; ANIMAL; PHYSIOLOGY;

ANIMALS; EPISTAXIS; HUMANS; LASER COAGULATION; LIGHT COAGULATION; RECURRENCE; REGIONAL BLOOD FLOW; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 33744970734     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361255     Document Type: Review

References (77)

1. Legg W. A case of hæmophilia complicated with multiple nævi. Lancet 1876; 2: 856-858.
2. Hanes FM. Mutiple hereditary telangiectases cause haemorrhage (hereditary haemorrhagic telangiectasia). Johns Hopkins Hosp Bull 1909; 20: 63-73.
3. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ et al. Diagnostic criteria for hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91(1): 66-67.
4. Reilly PJ, Nostrant TT. Clinical manifestations of hereditary haemorrhagic telangiectasia. Am J Gastroenterol 1984; 79(5): 363-367.
5. Saunders WH. Hereditary haemorrhagic telangiectasia, its familial pattern, clinical characteristics, and surgical treatment. Arch Otolaryngol 1962; 76: 245-260.
6. Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary haemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32(3): 291-297.
7. Pastor VC, Sanchez MD, Yague AR, Gil GR, Gomez PC. Hereditary haemorrhagic telangiectasia as a cause of iron-deficiency anemia. Rev Clin Esp 1993; 193(9): 483-484.
8. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary haemorrhagic telangiectasia. J Clin Invest 1999; 104(10): 1343-1351.
9. Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary haemorrhagic telangiectasia. Arch Dermatol 1973; 107(4): 571-573.
10. Saunders WH. Septal dermoplasty for control of nosebleeds caused by hereditary haemorrhagic telangiectasia or septal perforations. Trans Am Acad Ophthalmol Otolaryngol 1960; 64: 500-506.
11. Colver GB, Davies S, Bullock J. Infra red coagulation for bleeding mucosal telangiectasia. J Laryngol Otol 1992; 106: 992-993.
12. Lenz H, Eichler J. Wirkung des Argonlasers auf die Gefäße, Mikround Makrozirkulation der Schleimhaut der Hamsterbackentasche. Eine intravitalmikroskopische Studie. Laryngol Rhinol Otol (Stuttg) 1975; 54: 612-619.
13. Kluger PB, Shapshay SM, Hybels RL, Bohigian RK. Neodymium-YAG laser intranasal photocoagulation in hereditary haemorrhagic telangiectasia: an update report. Laryngoscope 1987; 97(12): 1397-1401.
14. Siegel MB, Keane WM, Atkins JF Jr, Rosen MR. Control of epistaxis in patients with hereditary haemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1991; 105(5): 675-679.
15. Haye R, Austad J. Hereditary haemorrhagic teleangiectasia - argon laser. Rhinology 1991; 29: 5-9.
16. Haye R, Austad J. Hereditary haemorrhagic teleangiectasia: unsuccessful treatment with the flashlamp-pulsed dye laser. Rhinology 1992; 30: 135-137.
17. Harries PG, Brockbank MJ, Shakespeare PG, Carruth JAS. Hereditary haemorrhagic teleangiectasia: unsuccessful treatment with the flashlamp-pulsed dye laser. J Laryngol Otol 1997; 111: 1038-1041.
18. Bergler W, Riedel F, Baker-Schreyer A, Juncker C, Hormann K. Argon plasma coagulation for the treatment of hereditary haemorrhagic telangiectasia. Laryngoscope 1999; 109(1): 15-20.
19. Geisthoff UW, Zenk J, Iro H. Nd:YAG-Laser- und Argon-Plasma-Koagulationsbehandlung im Vergleich zur Behandlung der rezidivierenden Epistaxis beim M. Osler. Lasermedizin 1999; 14: 57.
20. Geisthoff UW, Schneider G, Fischinger J, Plinkert PK. Hereditary haemorrhagic telangiectasia (Osler's disease). An interdisciplinary challenge. HNO 2002; 50(2): 114-128.
21. Pohar S, Mazeron JJ, Ghilezan M, Le Bourgeois JP, Pierquin B. Management of epistaxis in Rendu-Osler disease: is brachytherapy effective? Int J Radiat Oncol Biol Phys 1993; 27(5): 1073-1077.
22. Pizzi G, Turcato G, Polico R, Busetto M, Antonello M, Princivalli M. Brachytherapy of epistaxis in Rendu-Osler disease. Indications, technic, results. Radiol Med (Torino) 1995; 89(6): 861-864.
23. Maylin C, Sauvage JP, Baillet F, Chassagne D, Pierquin B. Rendu-Oster disease treated by endonasal radiotherapy (evaluation of 62 cases). Ann Otolaryngol Chir Cervicofac 1976; 93(1-2): 95-102.
24. McCaffrey TV, Kern EB, Lake CF. Management of epistaxis in hereditary haemorrhagic telangiectasia. Review of 80 cases. Arch Otolaryngol 1977; 103(11): 627-630.
25. Parkin JL, Dixon JA. Laser photocoagulation in hereditary haemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1981; 89(2): 204-208.
26. Parkin JL, Dixon JA. Argon laser treatment of head and neck vascular lesions. Otolaryngol Head Neck Surg 1985; 93(2): 211-216.
27. Osler W. On a family form of recurring epistaxis, associated with multiple telangiectases of the skin and mucous membranes. Johns Hopkins Hospital Bulletin 1901; 12: 333-337.
28. Strother CM, Newton TH. Percutaneous embolisation to control epistaxis in Rendu-Osler-Weber disease. Arch Otolaryngol 1976; 102(1): 58-60.
29. Elden L, Montanera W, Terbrugge K, Willinsky R, Lasjaunias P, Charles D. Angiographic embolisation for the treatment of epistaxis: A review of 108 cases. Otolaryngol Head Neck Surg 2003; 111: 44-50.
30. Parnes LS, Heeneman H, Vinuela F. Angiographic embolisation for the treatment of epistaxis: A review of 108 cases. Laryngoscope 1987; 97: 1312-1315.
31. Fischer M, Dietrich U, Labisch C, Zanella FE, Jahnke K. Critical evaluation of vascular embolisation in patients with Rendu-Osler disease. Laryngorhinootologie 1997; 76(8): 490-494.
32. Merland JJ, Melki JP, Chiras J, Riche MC, Hadjean E. Place of embolisation in the treatment of severe epistaxis. Laryngoscope 1980; 90: 1694-1704.
33. Seiffert A. Unterbindung der Arteria maxillaris interna. Zeitschr f Hals-, Nasen-u Ohrenh 1928; 22: 323-325.
34. Rosnagle RS, Yanagisawa E, Smith HW. Specific vessel ligation for epistaxis: survey of 60 cases. Laryngoscope 1973; 83: 517-525.
35. Schaitkin B, Strauss M, Houck JR. Epistaxis: medical versus surgical therapy: a comparison of efficacy, complications, an economic considerations. Laryngoscope 1987; 97: 1392-1396.
36. Golding-Wood PH. The role of arterial ligation in intractable epistaxis. J Laryngol Otol Suppl 1983; 8: 120-122.
37. Stecker RH, Lake CF. Hereditary haemorrhagic telangiectasia; review of 102 cases and presentation of an innovation to septodermoplasty. Arch Otolaryngol 1965; 82(5): 522-526.
38. Borsik M, Herbreteau D, Deffrennes D, Guichard JP, Aymard A, Merland JJ, et al. Treatment of epistaxis in Rendu-Osler disease by intramucosal injection of ethibloc. Ann Otolaryngol Chir Cervicofac 1992; 109(5): 273-276.
39. Martin H, Martin C. Injections of fibrin glue in severe epistaxis and Rendu-Osler disease. Ann Otolaryngol Chir Cervicofac 1984; 101(7): 561-563.
40. Jankowski R, Beaudouin E, Kanny E, Wayoff M, Moneret-Vautrin DA. Accidents d'hypersensibilite a la thrombine, consecutifs a l'emploi de colles biologiques. Ann Otolaryngol Chir Cervicofac 1992; 109: 95-99.
41. Lund VJ, Howard DJ. Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 1997; 111: 30-33.
42. Gluckman JL, Portugal LG. Modified Young's procedure for refractory epistaxis due to hereditary haemorrhagic telangiectasia. Laryngoscope 1994; 104(9): 1174-1177.
43. Hosni AA, Innes AJ. Hereditary haemorrhagic telangiectasia: Young's procedure in the management of epistaxis. J Laryngol Otol 1994; 108: 754-757.
44. Serrano E, Percodani J, Pessey JJ. Bilateral closure of the nasal cavity. An original surgical technique of treatment of severe recurrent epistaxis in Rendu-Osler disease. Ann Otolaryngol Chir Cervicofac 1998; 115(3): 169-173.
45. Saunders WH. Permanent control of nosebleeds in patients with hereditary haemorrhagic telangiectasia. Ann Intern Med 1960; 53: 147-152.
46. Whicker JH, Lake CF. Hemilateral rhinotomy in the treatment of hereditary haemorrhagic telangiectasia. Arch Otolaryngol 1972; 96(4): 319-321.
47. Laurian N, Kalmanovitch M, Shimberg R. Amniotic graft in the management of severe epistaxis due tho hereditary haemorrhagic telangiectasia. J Laryngol Otol 1979; 93(589): 585.
48. Milton CM, Shotton JC, Prmachandran DJ, Woodward BM, Fabre JW, Sergeant RJ. A new technique using cultured epithelial sheets for the management of epistaxis associated with hereditary haemorrhagic telangiectasia. J Laryngol Otol 1993; 107: 510-513.
49. Strauss M, Zohar Y, Laurian N. The management of severe recurrent epistaxis due to hereditary haemorrhagic telangiectasia using regional facial cutaneous flaps. J Laryngol Otol 1985; 99(4): 373-377.
50. Bridger GP, Baldwin M. Microvascular free flap in hereditary haemorrhagic telangiectasia. Arch Otolaryngol Head Neck Surg 1990; 116(1): 85-87.
51. Stocksted P, Khan M, Kjellerup PE. Dermoplastische Behandlung des Morbus Osler. HNO 1976; 24: 239-241.
52. Ulsø C, Vase P, Stocksted P. Long-term results of dermoplasty in the treatment of hereditary haemorrhagic telangiectasia. J Laryngol Otol 1983; 97: 223-226.
53. Zohar Y, Sadov R, Shvili Y, Talmi Y, Laurian N. Surgical management of epistaxis in hereditary haemorrhagic telangiectasia. Arch Otolaryngol Head Neck Surg 1987; 113(7): 754-757.
54. McCabe WP, Kelly AP, Jr. Management of epistaxis in Osler-Weber-Rendu disease: recurrence of telangiectases within a nasal skin graft. Plast Reconstr Surg 1972; 50(2): 114-118.
55. Helmi AM, El Ghazzawi IF, Mandour MA, Shehata MA. The effect of oestrogen on the nasal respiratory mucosa. An experimental histopathological and histochemical study. J Laryngol Otol 1975; 89: 1229-1241.
56. Harrison DFN. Familial haemmorrhagic telangiectases. A survey of cases treated by œstrogen therapy. J Laryngol Otol 1957; 71: 577-595.
57. Harrison DFN. Familial haemorrhagic telangiectasia. 20 cases treated with systemic oestrogen. Q J Med 1964; 33: 25-38.
58. Harrison DFN. Use of estrogen in treatment of familial haemorrhagic telangiectasia. Laryngoscope 1982; 92: 314-320.
59. Koch HJ, Escher GC, Lewis JS. Hormonal management of hereditary haemorrhagic telangiectasia. J Am Med Assoc 1952; 149: 1376-1380.
60. Budde R. A new method for managing epistaxis in Osler's disease (author's transl). HNO 1981; 29(3): 88-91.
61. Vase P. Estrogen treatment of hereditary haemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand 1981; 209(5): 393-396.
62. Vase P, Lorentzen M. Histological findings following oestrogen treatment of hereditary haemorrhagic telangiectasia. A controlled double-blind investigation. J Laryngol Otol 1983; 97(5): 427-429.
63. Bergler W, Sadick H, Gotte K, Riedel F, Hormann K. Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary haemorrhagic telangiectasia. Ann Otol Rhinol Laryngol 2002; 111(3 Pt 1): 222-228.
64. Flessa HC, Glueck HI. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu disease). Management of epistaxis in nine patients using systemic hormone therapy. Arch Otolaryngol 1977; 103(3): 148-151.
65. Menefee MG, Flessa HC, Glueck HI, Hogg SP. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu disease). An eletron microscopic study of the vascular lesions before and after therapy with hormones. Arch Otolaryngol 1975; 101(4): 246-251.
66. Rowley PT, Kurnick J, Cheville R. Hereditary haemorrhagic telangiectasia: aggravation by oral contraceptives? Lancet 1970; 1(7644): 474-475.
67. Haq AU, Glass J, Netchvolodoff CV, Bowen LM. Hereditary haemorrhagic telangiectasia and danazol. Ann Intern Med 1988; 109(2): 171.
68. Saba HI, Morelli GA, Logrono LA. Brief report: treatment of bleeding in hereditary haemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 330(25): 1789-1790.
69. Annichino-Bizzacchi JM, Facchini RM, Torresan MZ, Arruda VR. Hereditary haemorrhagic telangiectasia response to aminocaproic acid treatment Thromb Res 1999; 96(1): 73-76.
70. Jash DK. Epistaxis - topical use or epsilon-aminocaproic acid in its management. J Laryngol Otol 1973; 87(9): 895-898.
71. Klepfish A, Berrebi A, Schattner A. Intranasal tranexamic acid treatment for severe epistaxis in hereditary haemorrhagic telangiectasia. Arch Intern Med 2001; 161(5): 767.
72. Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary haemorrhagic telangiectasia. N Engl J Med 2001; 345(12): 926.
73. Korzenik JR, Topazian MD, White R. Treatment of bleeding in hereditary haemorrhagic telangiectasia with aminocaproic acid. N Engl J Med 1994; 331(18): 1236.
74. Peery WH. Clinical spectrum of hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu disease). Am J Med 1987; 82(5): 989-997.
75. Messmore HL, Coyne E, Wehrmacher WH, Demir AM, Fareed J. Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review. Curr Pharm Des 2004; 10(9): 1001-10.
76. Mourao PA. Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives. Curr Pharm Des 2004; 10(9): 967-81.
77. Muro S, Muzykantov VR. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr Pharm Des 2005; 11(18): 2383-401.